These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31082272)

  • 1. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
    Kotecki N; Gombos A; Awada A
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):447-454. PubMed ID: 31082272
    [No Abstract]   [Full Text] [Related]  

  • 2. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
    Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
    Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
    [No Abstract]   [Full Text] [Related]  

  • 5. Neratinib for the treatment of HER2-positive early stage breast cancer.
    Echavarria I; López-Tarruella S; Márquez-Rodas I; Jerez Y; Martin M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):669-679. PubMed ID: 28649882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer.
    Schwartz NRM; Flanagan MR; Babigumira JB; Steuten LM; Roth JA
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1133-1139. PubMed ID: 31556818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.
    Delaloge S; Cella D; Ye Y; Buyse M; Chan A; Barrios CH; Holmes FA; Mansi J; Iwata H; Ejlertsen B; Moy B; Chia SKL; Gnant M; Smichkoska S; Ciceniene A; Martinez N; Filipović S; Ben-Baruch NE; Joy AA; Langkjer ST; Senecal F; de Boer RH; Moran S; Yao B; Bryce R; Auerbach A; Fallowfield L; Martin M
    Ann Oncol; 2019 Apr; 30(4):567-574. PubMed ID: 30689703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER
    Sudhan DR; Schwarz LJ; Guerrero-Zotano A; Formisano L; Nixon MJ; Croessmann S; González Ericsson PI; Sanders M; Balko JM; Avogadri-Connors F; Cutler RE; Lalani AS; Bryce R; Auerbach A; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(2):771-783. PubMed ID: 30274983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
    Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
    Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
    Lüftner D; Tesch H; Schmidt M; Hartkopf AD; Streicher S; Resch A; Genovese L; Rosé C; Valenti R; Harbeck N
    Eur J Cancer; 2021 Jun; 150():268-277. PubMed ID: 33971386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer.
    Singh H; Walker AJ; Amiri-Kordestani L; Cheng J; Tang S; Balcazar P; Barnett-Ringgold K; Palmby TR; Cao X; Zheng N; Liu Q; Yu J; Pierce WF; Daniels SR; Sridhara R; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Aug; 24(15):3486-3491. PubMed ID: 29523624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
    Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
    Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
    Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib for HER2-positive breast cancer with an overlooked option.
    Guo L; Shao W; Zhou C; Yang H; Yang L; Cai Q; Wang J; Shi Y; Huang L; Zhang J
    Mol Med; 2023 Oct; 29(1):134. PubMed ID: 37803271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive, HER2-positive early-stage breast cancer.
    Blanter J; Baldwin E; Patel R; Sheng T; Tiersten A
    Breast Cancer Res Treat; 2024 Nov; 208(2):461-466. PubMed ID: 39153126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers.
    Musolino A; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Vattiato R; Sgargi P; Falcini F; Caminiti C; Michiara M; Leonardi F
    Cancer Treat Rev; 2016 Feb; 43():1-7. PubMed ID: 26827687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
    Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
    Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
    Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
    Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.